Taysha Gene Therapies, Inc.
TSHABiological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001806310
Revenue FY2025
$10.0M
Net Income
$(109.0M)
EPS (Basic)
$-0.34
Net Margin
-1115.3%
ROE
-44.1%
Total Equity
$247.0M
Shares Out
326M
Taysha Gene Therapies, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 8 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Tybourne Capital Management (HK)
Tybourne Capital Management (HK)
$12.1M
39.1%
(9.6%)
RA Capital Management
RA Capital Management
$160.4M
1.0%
—
Baker Bros. Advisors
Baker Bros. Advisors
$27.3M
0.1%
—
OrbiMed Advisors
OrbiMed Advisors
$13.6M
0.1%
NEW
Polen Capital Management
Polen
$3.3M
0.0%
+53.0%
Holocene Advisors
Holocene Advisors
$3.5M
0.0%
NEW
Adage Capital Management
Adage Capital Management
$3.8M
0.0%
NEW
Alps Advisors
Alps Advisors
$2.0M
0.0%
+30.3%
Insider Transactions
Reading stored insider transactions…